NCT01260246

Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes

Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes.

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled trial evaluating the impact of sitagliptin therapy in patients with concomitant type 2 diabetes and non-alcoholic steatohepatitis (NASH) on improving liver disease based on biopsy results. The effect of sitagliptin on other measures such as hormones modifying insulin release and sensitivity (termed adipocytokines), fat distribution, and biomarkers of cardiovascular risk will also be evaluated.

Conditions

• Type 2 Diabetes
• Nonalcoholic Steatohepatitis

Interventions

Type	Name	Description
DRUG	sitagliptin	pill, 100mg/daily for 6 months
DRUG	placebo	placebo match for 6 months

Timeline

• Start date: 2010-12-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2010-12-15
• Last updated: 2017-03-14

Locations

1 site across 1 country: Canada